Non-interventional post-marketing safety study on the long-term safety of HyQvia (global)
Lina Morales Laguado(Takeda (United States)), Leman Yel(Children's Hospital of Philadelphia), András Nagy(University of Szeged), Heinz Leibl(Takeda (United States)), Barbara McCoy(Baxalta (United States)), Christopher J. Rabbat(Abivax (France)), Katharina Fielhauer(Baxalta (United States))
DOAJ (DOAJ: Directory of Open Access Journals)
June 1, 2018
Cited by 0
Related Papers
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms
|Cardiovascular Drugs and Therapy|2024|38
Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference
|Journal of Clinical Immunology|2021|28
Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study
|Journal of Crohn s and Colitis|2025|10
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
|Immunotherapy|2024|5
Vitamin D and breast cancer
|Orvosi Hetilap|2014|4